Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights

The field of multiple myeloma is rapidly evolving and can be credited to an increased understanding of the biology of the disease leading to an improvement in patients outcomes. Despite vast advances, the clinical management of patients with multiple myeloma remains challenging, namely resistance in relapsed patients as well as the identification of predictive and prognostic biomarkers.

In this podcast following the virtual annual American Society of Hematology (ASH) 2020 meeting, we hear from three leading experts in multiple myeloma, Niels van de Donk of the University Medical Center, Amsterdam, Netherlands, Yi Lin of Mayo Clinic, Rochester, MN and Maria-Victoria Mateos, of the University of Salamanca, Salamanca, Spain, who address the latest therapeutic approaches presented at ASH 2020 annual meeting.